title: Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia.
abstract: The objective of this study was to investigate the diphtheria-tetanus-pertussis and/or measles-mumps antibody titers before and after vaccination at various time points of acute lymphoblastic leukemia (ALL) therapy and to suggest an appropriate vaccination approach for ALL patients. The authors studied 37 ALL patients and 14 healthy control subjects, divided into three groups. In group 1 (newly diagnosed patients), baseline anti-diphtheria, anti-tetanus, and anti-pertussis titers were determined. Patients in group 2 (on maintenance chemotherapy) and group 3 (patients not receiving therapy for 3-6 months) were vaccinated with diphtheria-tetanus with or without acellular pertussis; group 3 and control subjects were also given measles-mumps-rubella vaccine. Preimmunization and 1-month postimmunization titers were drawn. Preimmunization anti-diphtheria and anti-tetanus antibody titers between the groups and the controls were statistically similar. The seropositivity rate for anti-measles antibody in group 3 was significantly lower than controls. After vaccination, all of the patients developed protective anti-diphtheria and anti-tetanus antibody titers. The seroconversion rates of group 3 and controls for anti-measles and anti-mumps antibodies were statistically similar. The results showed that patients on maintenance therapy and after cessation of therapy made good antibody responses to diphtheria and tetanus toxoids, but response to measles and mumps vaccines was not as sufficient as toxoid vaccines. Children with ALL can receive the appropriate vaccines during and after maintenance treatment.
authors.affiliation: Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey. tugba.er@turk.net
authors.forename: Tugba Erener
authors.initials: TE
authors.lastname: Ercan
authors.forename: Lebriz Yüksel
authors.initials: LY
authors.lastname: Soycan
authors.forename: Hilmi
authors.initials: H
authors.lastname: Apak
authors.forename: Tiraje
authors.initials: T
authors.lastname: Celkan
authors.forename: Alp
authors.initials: A
authors.lastname: Ozkan
authors.forename: Emine
authors.initials: E
authors.lastname: Akdenizli
authors.forename: Ozgur
authors.initials: O
authors.lastname: Kasapçopur
authors.forename: Inci
authors.initials: I
authors.lastname: Yildiz
mesh_terms: D000293:Adolescent; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007114:Immunization / Q000379:methods; D008458:Measles Vaccine / Q000276:immunology / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000276:immunology*; D012016:Reference Values; D012411:Rubella Vaccine / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D008458:Measles Vaccine; D012411:Rubella Vaccine